Inventiva (IVA)
(Delayed Data from NSDQ)
$2.11 USD
-0.05 (-2.32%)
Updated Aug 9, 2024 03:55 PM ET
4-Sell of 5 4
F Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
IVA 2.11 -0.05(-2.32%)
Will IVA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IVA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IVA
Down -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA)
Humana (HUM) Ups '23 Medicare Advantage Membership Growth View
IVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why You Should Retain Centene (CNC) in Your Portfolio Now
What You Need to Know From UnitedHealth's (UNH) Latest Outlook
Cigna (CI) Rises 18.9% in 6 Months: More Growth in Store?
Other News for IVA
Stifel Nicolaus Sticks to Its Buy Rating for Inventiva (IVA)
Inventiva Reports Preliminary 2024 First-Half Financial Information?
Inventiva’s First-Half 2024 Financial Snapshot
Inventiva reports preliminary HI 2024 data
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor